IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.30
+0.00%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+25.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 31, 2026 | BERMAN DENNIS N · director | M-Exempt | 21,854 | $1.26 |
| Jun 30, 2026 | BERMAN DENNIS N · director | A-Award | 155,000 | $1.91 |
| Jun 30, 2026 | Munshi Amit · director | A-Award | 155,000 | $1.91 |
| Jun 30, 2026 | Aurentz Vincent · director | A-Award | 155,000 | $1.91 |
| Jun 30, 2026 | Bellini Roberto · director | A-Award | 155,000 | $1.91 |
| Jun 30, 2026 | Kush Arvind · director | A-Award | 155,000 | $1.91 |
| Jun 30, 2026 | Canner David · director | A-Award | 155,000 | $1.91 |
| Jan 7, 2026 | McIntyre David · officer: Chief Financial Officer | A-Award | 986,319 | $2.01 |
| Jan 7, 2026 | Cabell Christopher · officer: President & Head of R&D | A-Award | 900,117 | $2.01 |
| Jan 7, 2026 | Iwicki Mark T · director, officer: Chief Executive Officer | A-Award | 4,982,706 | $2.01 |
| Nov 24, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. · 10 percent owner | Purchase | 2,068,965 | $1.45 |
| Aug 28, 2025 | Munshi Amit · director | A-Award | 57,265 | $0.00 |
| Jul 2, 2025 | BERMAN DENNIS N · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Canner David · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Munshi Amit · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Kush Arvind · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Aurentz Vincent · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Bellini Roberto · director | A-Award | 108,176 | $1.95 |
| Jul 2, 2025 | Cabell Christopher · officer: President & Head of R&D | A-Award | 1,100,705 | $2.97 |
| Jul 2, 2025 | Iwicki Mark T · director, officer: Chief Executive Officer | A-Award | 602,346 | $2.97 |
| Jul 2, 2025 | Aurentz Vincent · director | A-Award | 134,427 | $2.97 |
| Apr 16, 2025 | McIntyre David · officer: Chief Financial Officer | A-Award | 1,775,539 | $2.00 |
| Feb 25, 2025 | Cabell Christopher · officer: President & Head of R&D | A-Award | 1,100,705 | $2.23 |
| Feb 25, 2025 | Aurentz Vincent · director | A-Award | 134,427 | $2.23 |
| Feb 25, 2025 | Iwicki Mark T · director, officer: Chief Executive Officer | A-Award | 602,346 | $2.23 |
| Feb 19, 2025 | Munshi Amit · director | A-Award | 116,585 | $2.35 |
| Feb 19, 2025 | Munshi Amit · director | A-Award | 56,600 | $2.35 |
| Feb 19, 2025 | Canner David · director | A-Award | 116,585 | $2.35 |
| Feb 19, 2025 | Canner David · director | A-Award | 22,640 | $2.35 |
| Feb 19, 2025 | BERMAN DENNIS N · director | A-Award | 39,620 | $2.35 |
Institutional positioning
13F filings over the trailing two quarters
New 58Increased 85Reduced 38Sold out 14
| Filer | Action | Shares | Filed |
|---|---|---|---|
| SANDS CAPITAL VENTURES, LLC | Unchanged | 13,018,965 | May 8, 2026 |
| Sands Capital Alternatives, LLC | Unchanged | 13,018,965 | Aug 13, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Unchanged | 10,875,000 | May 14, 2026 |
| Soleus Capital Management, L.P. | Unchanged | 10,875,000 | Aug 11, 2026 |
| Trails Edge Capital Partners, LP | Increased | 9,051,318 | Aug 14, 2026 |
| Fairmount Funds Management LLC | Unchanged | 8,625,000 | Aug 14, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 8,625,000 | May 15, 2026 |
| Trails Edge Capital Partners, LP | Increased | 8,057,345 | May 15, 2026 |
| BlackRock, Inc. | Increased | 7,768,057 | Aug 7, 2026 |
| ADAR1 Capital Management, LLC | Increased | 7,387,205 | Aug 14, 2026 |
| ADAR1 CAPITAL MANAGEMENT, LLC | Reduced | 6,606,572 | May 18, 2026 |
| BLACKROCK, INC. | Increased | 6,303,433 | May 13, 2026 |
| BLACKSTONE INC. | Unchanged | 5,938,276 | May 15, 2026 |
| Blackstone Inc. | Unchanged | 5,938,276 | Aug 14, 2026 |
| Siren, L.L.C. | Unchanged | 5,850,000 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 31, 2026